MOTUS GI HOLDINGS INC - MOTS STOCK NEWS

Motus GI Holdings, Inc. (NASDAQ: MOTS) announced its management team's presentation at the Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 3:30 p.m. Eastern Time. The company specializes in medical technology, focusing on endoscopy solutions that enhance clinical outcomes and cost-efficiency in diagnosing gastrointestinal conditions. The presentation will be available via a live webcast and later archived on the company's website, motusgi.com.

Motus GI Holdings (NASDAQ: MOTS) has appointed Sonja Nelson, CPA, to its Board of Directors and as Chair of the Audit Committee. Nelson brings over 25 years of financial and operational experience in biotechnology and pharmaceutical sectors, notably her role in the merger between NantKwest and Immunity Bio. David Hochman, Chairman of Motus GI, expressed confidence that her leadership will significantly benefit the company's growth trajectory. This strategic move reflects Motus GI's commitment to enhancing its governance as it navigates future opportunities in the gastrointestinal solutions market.

Motus GI (NASDAQ: MOTS) has initiated the first patient enrollment in a European Union study evaluating the Pure-Vu System, designed to enhance colonoscopy outcomes for patients with poor bowel preparation. Targeting approximately 44 patients at two sites, the study assesses the effectiveness of a low-volume bowel preparation combined with the Pure-Vu System. Successful results could position the Pure-Vu System as a key solution for challenging patient populations, expanding its commercial potential in a market where 6 million colonoscopies were performed in the EU in 2019.

Motus GI Holdings (NASDAQ: MOTS) recently published findings from the REDUCE study in BMC Gastroenterology, demonstrating a 97% clinical success rate for its Pure-Vu system in enhancing bowel preparation during colonoscopy. The study enrolled 95 hospitalized patients and showed significant improvements in colon cleansing, with 100% success in the left colon segment. The findings support Pure-Vu's potential to reduce hospital costs and improve patient care. CEO Tim Moran highlighted the system's role in delivering timely, effective diagnostic procedures.

Motus GI Holdings, a medical technology company focused on gastrointestinal solutions, has signed an agreement with Sinai Hospital of Baltimore to adopt the Pure-Vu System for inpatient colonoscopy procedures. This system aims to enhance efficiency and clinical outcomes, especially for patients with inadequate bowel preparation. With the FDA clearance and CE Mark in the EU, the Pure-Vu System has demonstrated over 95% bowel cleanliness rates in clinical studies. The partnership marks a significant milestone in Motus GI's expansion within large integrated delivery networks.

Motus GI reported a strong financial update for Q1 2021, achieving a 40% revenue growth compared to Q4 2020, with total revenues of approximately $51,000, up from $28,000 in Q1 2020. The company received FDA 510(k) clearance for its Pure-Vu Upper GI disposable sleeve, expanding its market opportunities. Additionally, it signed agreements with two prominent medical centers for minimum purchase orders. A net loss of $4.6 million was recorded, improving from a loss of $6.5 million last year, with cash reserves totaling $27.7 million.

Motus GI Holdings announced a new cost-effectiveness analysis of its Pure-Vu System, published in Cost Effectiveness and Resource Allocation. The system can save the U.S. healthcare system an estimated $833-$992 per patient compared to standard outpatient colorectal cancer (CRC) screening. Approximately 3.75 million out of 15 million annual colonoscopies in the U.S. are inadequately prepped. The analysis suggests that the Pure-Vu System could reduce CRC incidence and enhance patient quality of life by ensuring timely detection.

Motus GI Holdings, Inc. (NASDAQ: MOTS) announced FDA 510(k) clearance for its Pure-Vu® System, enhancing visibility during upper gastrointestinal (GI) endoscopy procedures. This version is compatible with gastroscopes, aimed at improving clinical outcomes in roughly 400,000 annual upper GI bleed cases in the U.S. The technology helps remove blood and debris, assisting physicians in identifying bleed sources more effectively. The Pure-Vu System has shown over 95% bowel cleanliness rates in prior studies, providing a promising innovation in endoscopic procedures.

Motus GI Holdings (NASDAQ: MOTS) will release its first quarter financial results on May 13, 2021, after market close. The Company specializes in medical technology, focusing on endoscopy solutions aimed at improving clinical outcomes and cost efficiency in managing gastrointestinal conditions. Following the results announcement, management will host a conference call at 4:30 p.m. ET to discuss the outcomes and provide recent corporate updates.